Navigation Links
Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
Date:4/15/2008

AMSTERDAM, April 15 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announced today that the U.S. Food and Drug Administration (FDA) has granted its product Rhitol(TM) Orphan Drug Designation for the treatment of chronic Graft versus Host Disease (GvHD). This complication of allogeneic bone marrow transplantation is highly disabilitating and can become life threatening when the patient is unresponsive to steroid treatment. Rhitol(TM) has completed a multicenter phase I/II study for patients with severe steroid resistant chronic GvHD. A phase III study is anticipated to start in 2008.

"The decision by the FDA to grant Rhitol(TM) orphan drug designation in this area of blood cancer with unmet medical need advances our efforts to develop an innovative treatment" says Dr. Manja Bouman, Chief Executive Officer of Kiadis Pharma.

The FDA's orphan drug designation is reserved for new therapies being developed to treat diseases or conditions that affect fewer than 200,000 people in the United States. The orphan drug designation provides for an accelerated review process, tax benefits, exemption from user fees and a seven-year period of market exclusivity in the United States after product approval.

About Rhitol(TM)

Rhitol(TM) is under development as a treatment for patients with chronic GvHD resistant or intolerant to immunosuppressive agents. Rhitol(TM) treatment targets activated T cells that cause GvHD and results in immune modulation within patients with chronic GvHD, restores immune tolerance and attempts to achieve disease remission.

About chronic GvHD

GvHD is a condition that can develop after allogeneic bone marrow transplantation and resembles an autoimmune disease. Graft versus Host Disease is caused by immune cells from the donor graft attacking the patient's tissues and organs. Chronic GvHD usually develops some time after the transplantation and is generally treated by immunosuppressive drugs, such as ster
'/>"/>

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Sept. 15, 2014  iVinci Health LLC, the company ... Revenue Management system, branded as VisitPay®, has successfully closed ... the launch of a new extension to VisitPay® – ... easy and convenient way for patients to manage their ... by them and their families. The new ...
(Date:9/15/2014)... 15, 2014 Applied Silicone Corporation, ... for the medical device and critical healthcare market, ... the implantable medical device market. The Dual ... delivering a silicone gel with improved fracture resistance, ... technology consists of two crosslinked networks working in ...
(Date:9/15/2014)... septiembre de 2014 La segunda anual International ... 12 al 18 de octubre. Como iniciativa conjunta de la ... compañías miembro s, la IPAW se ha diseñado para: ... a la colección de fuentes de plasma , Reconocimiento ... y mejorar las vidas , Aumento del conocimiento sobre ...
(Date:9/14/2014)... 2014 UMBC’s Biotechnology Graduate Programs’ ... October 21, 2014, from 12:00 to 1:00 p.m. EDT. ... innovative curriculum and practice-oriented instruction, designed for working professionals. ... help advance their career in the biotechnology industry. , ... , About UMBC’s Biotechnology Graduate Programs, UMBC offers ...
Breaking Biology Technology:iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 2iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 3Applied Silicone Launches Silicone Gel System with Dual Matrix Technology 2La International Plasma Awareness Week será una celebración para los donantes 2La International Plasma Awareness Week será una celebración para los donantes 3UMBC Biotechnology Graduate Programs’ Virtual Info Session, October 21, 2014 2
... ... SAN FRANCISCO, Calif., Sept. 8 Proteolix, Inc., a,leader in ... pathways in cancer and autoimmune diseases, today,announced the successful completion ... round was led by new investor Nomura Phase4 Ventures.,New investor ...
... appointed A.J. Whalen as Solutions Director. , ... ... www.symphony-consulting.com [Symphony Management Consulting] announced that it has appointed ... joins Symphony from Wellesley Information Services (WIS) where he was ...
... of a study led by Yuntao Wu, assistant professor in ... community is one step closer to understanding how the human ... which is caused by HIV, affected more than 33 million ... , In the Sept. 5 issue of the journal ...
Cached Biology Technology:Proteolix Raises $79 Million in Series C Financing 2Proteolix Raises $79 Million in Series C Financing 3Symphony Managemnt Consulting Hires New Solutions Director 2Researchers decode viral process that prepares cells for HIV infection 2
(Date:9/15/2014)... -- Speed and agility are hallmarks of the cheetah: The ... to accelerate to 60 mph in just a few seconds. ... its legs in tandem, bounding until it reaches a full ... bounding that they,ve successfully implemented in a robotic cheetah ... that weighs about as much as its feline counterpart. The ...
(Date:9/15/2014)... in German . ... it doubles, divides in the middle and originates two ... that cells of the same kind are similarly sized ... University of Vienna, revealed that two non-model bacteria divide ... the naked eye. These findings have been published in ...
(Date:9/15/2014)... Philadelphia, PA, September 15, 2014 Schizophrenia is generally ... it shares many risk factors, both genetic and environmental, ... disability. , The normal path for brain development is ... of genes and a wide range of environmental factors. ... and patient populations are required in order to map ...
Breaking Biology News(10 mins):Run, cheetah, run 2Run, cheetah, run 3Think big! Bacteria breach cell division size limit 2Brain Development in Schizophrenia Strays from the Normal Path 2
... are published in the journal Nature Communications , on ... adults in France, and its constitutive mechanisms are still not ... is coordinated by a specialised part of the brain (the ... In this way, after a period of excessive food intake ...
... John Wiley & Sons, Inc., today announced that it will ... The EMBO Journal , EMBO reports and ... three leading scientific journals alongside EMBO Molecular Medicine , ... Journal is EMBO,s flagship title. Since its launch in ...
... damage is an important mechanism of glioma. X-ray cross-complementing ... participates in the base excision repair pathway. To date, ... between the XRCC1 polymorphisms and risk of cancers such ... of studies that focused on glioma is relatively small. ...
Cached Biology News:Obesity: A new appetite-increasing mechanism discovered 2Wiley and EMBO announce expanded partnership 2
Improve inventory management with stainless steel red cell canisters; ensure product safety with CO2 or LN2 backup systems. A complete solution for your blood banking needs....
... Orbital Shakers combine high durability and ... power. The patented triple-counterbalanced heavy-duty ... to run with heavy out-of-balance loads. ... reduces contamination. The heavy stainless ...
... T4 Polynucleotide Kinase (PNK) catalyzes ... ATP to the 5'-hydroxyl of single- ... 3'-monophosphates. The enzyme also removes the ... and deoxyribonucleoside 3', 5'-diphosphates to form ...
The Cellject Elecroporator is suitable for all cell types including embryo, mammalian, plant, yeast and bacterial. Its has highly user-freindly programing and can be used remotely, for example in a l...
Biology Products: